CDMO - September 24, 2025
PolyPeptide Group achieves milestone in Malmö expansion
PolyPeptide Group has announced the successful delivery and installation of pre-built modules at its Malmö, Sweden facility.
Acquisition - September 22, 2025
Kancera to seek stakeholders for a reverse take over
The company's board has decided to initiate a process to seek potential stakeholders for a reverse take over of the company with the aim to materialize the value of its public listing.
Pharma Business - September 22, 2025
Sobi’s Tryngolza approved in the EU for familial chylomicronemia syndrome
Sobi and Ionis Pharmaceuticals have announced that Tryngolza (olezarsen) has been approved in the European Union (EU) as an adjunct to diet in adult patients for the treatment of genetically confirmed familial chylomicronemia syndrome (FCS).
Pharma Business - September 17, 2025
EU approval of updated label of Novo Nordisk’s oral semaglutide
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has approved an update to the Rybelsus (oral semaglutide) label to reflect the cardiovascular benefits seen in the SOUL trial.
Agreement - September 17, 2025
ALK enters partnership with GenSci
ALK has announced a partnership agreement with China-based Changchun GeneScience Pharmaceutical to develop and commercialize ALK’s house dust mite allergy immunotherapy (AIT) products in Mainland China.
Pharma Business - September 12, 2025
Lundbeck sharpens its commercial focus
Lundbeck will transition its operations to a partnership model in 27 markets in Europe and International Operations through new partnerships with Swixx Group, Zuellig Pharma, and NewBridge Pharmaceuticals.
